Stryker ROA 2006-2018 | SYK
Current and historical return on assets (ROA) values for Stryker (SYK) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Stryker ROA for the three months ending September 30, 2018 was 12.26%.
| Stryker ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2018-09-30 | $1.24B | $22.08B | 5.62% |
| 2018-06-30 | $1.08B | $21.57B | 4.94% |
| 2018-03-31 | $1.02B | $22.13B | 4.68% |
| 2017-12-31 | $1.02B | $22.20B | 4.77% |
| 2017-09-30 | $1.78B | $21.49B | 8.50% |
| 2017-06-30 | $1.70B | $21.29B | 8.25% |
| 2017-03-31 | $1.69B | $20.52B | 8.27% |
| 2016-12-31 | $1.65B | $20.44B | 8.15% |
| 2016-09-30 | $1.66B | $20.19B | 8.66% |
| 2016-06-30 | $1.61B | $20.52B | 8.88% |
| 2016-03-31 | $1.62B | $19.67B | 9.42% |
| 2015-12-31 | $1.44B | $16.22B | 8.78% |
| 2015-09-30 | $1.18B | $15.92B | 7.07% |
| 2015-06-30 | $0.93B | $16.82B | 5.47% |
| 2015-03-31 | $0.67B | $16.58B | 3.90% |
| 2014-12-31 | $0.52B | $17.28B | 3.02% |
| 2014-09-30 | $0.64B | $17.52B | 3.85% |
| 2014-06-30 | $0.69B | $17.23B | 4.29% |
| 2014-03-31 | $0.77B | $16.16B | 5.05% |
| 2013-12-31 | $1.01B | $15.74B | 6.81% |
| 2013-09-30 | $0.89B | $14.88B | 6.29% |
| 2013-06-30 | $1.14B | $14.38B | 8.37% |
| 2013-03-31 | $1.25B | $14.09B | 9.57% |
| 2012-12-31 | $1.30B | $13.21B | 10.24% |
| 2012-09-30 | $1.43B | $12.78B | 11.51% |
| 2012-06-30 | $1.40B | $12.26B | 11.46% |
| 2012-03-31 | $1.39B | $12.46B | 11.50% |
| 2011-12-31 | $1.35B | $12.15B | 11.43% |
| 2011-09-30 | $1.24B | $12.08B | 10.82% |
| 2011-06-30 | $1.25B | $11.60B | 11.23% |
| 2011-03-31 | $1.26B | $11.23B | 11.71% |
| 2010-12-31 | $1.27B | $10.90B | 12.17% |
| 2010-09-30 | $1.28B | $10.77B | 12.84% |
| 2010-06-30 | $1.18B | $10.06B | 12.48% |
| 2010-03-31 | $1.15B | $10.10B | 12.92% |
| 2009-12-31 | $1.11B | $9.07B | 13.40% |
| 2009-09-30 | $1.08B | $8.46B | 13.67% |
| 2009-06-30 | $1.12B | $7.92B | 14.65% |
| 2009-03-31 | $1.14B | $7.59B | 14.80% |
| 2008-12-31 | $1.15B | $7.60B | 14.85% |
| 2008-09-30 | $1.15B | $7.58B | 14.94% |
| 2008-06-30 | $1.10B | $8.03B | 14.70% |
| 2008-03-31 | $1.07B | $7.75B | 15.01% |
| 2007-12-31 | $1.02B | $7.35B | 15.25% |
| 2007-09-30 | $0.97B | $6.86B | 15.38% |
| 2007-06-30 | $0.93B | $6.42B | 15.63% |
| 2007-03-31 | $0.87B | $6.08B | 15.57% |
| 2006-12-31 | $0.78B | $5.87B | 14.56% |
| 2006-09-30 | $0.73B | $5.40B | 14.21% |
| 2006-06-30 | $0.66B | $5.11B | 13.56% |
| 2006-03-31 | $0.63B | $4.99B | 13.48% |
| 2005-12-31 | $0.64B | $4.99B | 14.61% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $62.695B | $12.444B |
| Stryker Corporation is one of the world's leading medical technology companies and together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $125.437B | 25.42 |
| Medtronic (MDT) | Ireland | $117.248B | 17.53 |
| Boston Scientific (BSX) | United States | $52.155B | 26.36 |
| Baxter (BAX) | United States | $37.585B | 24.27 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.487B | 13.93 |
| ResMed (RMD) | United States | $16.792B | 32.02 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.606B | 0.00 |
| Canopy Growth (CGC) | Canada | $10.104B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.180B | 45.91 |
| Hill-Rom Holdings (HRC) | United States | $6.608B | 20.68 |
| Aurora Cannabis (ACB) | Canada | $6.428B | 33.90 |
| Perrigo (PRGO) | Ireland | $6.245B | 9.48 |
| Haemonetics (HAE) | United States | $5.216B | 45.87 |
| ICU Medical (ICUI) | United States | $4.878B | 27.18 |
| Insulet (PODD) | United States | $4.428B | 0.00 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.141B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.252B | 0.00 |
| Neogen (NEOG) | United States | $3.150B | 48.38 |
| Hutchison China MediTech (HCM) | China | $2.945B | 0.00 |
| National Vision Holdings (EYE) | United States | $2.566B | 49.63 |
| NuVasive (NUVA) | United States | $2.469B | 22.98 |
| Quidel (QDEL) | United States | $2.084B | 27.17 |
| NxStage Medical (NXTM) | United States | $1.901B | 0.00 |
| Aphria (APHA) | $1.668B | 74.22 | |
| Phibro Animal Health (PAHC) | United States | $1.294B | 18.32 |
| AtriCure (ATRC) | United States | $1.222B | 0.00 |
| VAREX IMAGING (VREX) | United States | $1.060B | 21.23 |
| Cardiovascular Systems (CSII) | United States | $1.013B | 1457.00 |
| PetIQ (PETQ) | United States | $0.781B | 20.25 |
| Cerus (CERS) | United States | $0.771B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.747B | 42.03 |
| Meridian Bioscience (VIVO) | United States | $0.713B | 22.73 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.662B | 21.24 |
| Omeros (OMER) | United States | $0.658B | 0.00 |
| Surmodics (SRDX) | United States | $0.642B | 97.18 |
| Lantheus Holdings (LNTH) | United States | $0.637B | 19.73 |
| NanoString Technologies (NSTG) | United States | $0.624B | 0.00 |
| MacroGenics (MGNX) | United States | $0.520B | 0.00 |
| Quanterix (QTRX) | United States | $0.467B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.458B | 22.48 |
| Owens & Minor (OMI) | United States | $0.453B | 5.12 |
| Evolus (EOLS) | United States | $0.436B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.375B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.327B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.322B | 20.85 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.279B | 0.00 |
| Bovie Medical (APYX) | United States | $0.278B | 0.00 |
| Vapotherm (VAPO) | United States | $0.273B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.244B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.226B | 305.00 |
| Rockwell Medical (RMTI) | United States | $0.198B | 0.00 |
| Fonar (FONR) | United States | $0.139B | 7.00 |
| Chimerix (CMRX) | United States | $0.137B | 0.00 |
| Surface Oncology (SURF) | United States | $0.136B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.121B | 0.00 |
| United-Guardian (UG) | United States | $0.090B | 18.85 |
| Female Health (VERU) | United States | $0.084B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.065B | 18.07 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.059B | 0.00 |
| CAS Medical Systems (CASM) | United States | $0.056B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.056B | 0.00 |
| ImmuCell (ICCC) | United States | $0.041B | 0.00 |
| Neurotrope (NTRP) | United States | $0.031B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.021B | 0.00 |
| Senestech (SNES) | United States | $0.019B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.017B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.015B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.010B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
